Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?
Q2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
a. Paclitaxel in combination with a platinum-based compound
b. Platinum-based therapy alone (cisplatin or carboplatin)
c. Bevacizumab in combination with paclitaxel and carboplatin
d. Olaparib
e. Olaparib + Bevacizumab
f. Niraparib
g. Rucaparib
Q3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.
Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
Q5. If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:
a. Olaparib
b. Olaparib + Bevacizumab
c. Niraparib
d. Other treatments
